
KLOW is a precision quad-peptide research blend combining BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg in a single sterile vial. Each component targets a distinct but complementary repair pathway, making KLOW one of the most comprehensive multi-peptide formulations available.
Key Research Areas
- BPC-157 10mg โ cytoprotection, gut-brain axis repair, angiogenesis and FAK-paxillin pathway activation
- TB-500 10mg โ systemic actin regulation, cell migration and soft tissue recovery
- GHK-Cu 50mg โ collagen and elastin synthesis, antioxidant enzyme activation and gene expression modulation
- KPV 10mg โ NF-ฮบB inhibition, pro-inflammatory cytokine reduction and mucosal healing
- Synergistic multi-pathway approach: local repair + systemic recovery + regeneration + anti-inflammation
Mechanism of Action
KLOW combines four peptides acting on complementary pathways: BPC-157 activates FAK-paxillin and NO signalling for local repair; TB-500 sequesters G-actin for systemic cell migration; GHK-Cu activates TGF-ฮฒ and collagen synthesis; KPV blocks NF-ฮบB to suppress inflammation. Together they provide a broad-spectrum regenerative and anti-inflammatory effect.
